These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23157726)

  • 1. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
    Galaup A; Paci A
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
    Główka FK; Romański M; Wachowiak J
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.
    Hilger RA; Baumgart J; Scheulen ME; Trenschel R; Strumberg D; Seeber S; Beelen DW
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):654-5. PubMed ID: 15598037
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
    ten Brink MH; Zwaveling J; Swen JJ; Bredius RG; Lankester AC; Guchelaar HJ
    Drug Discov Today; 2014 Oct; 19(10):1572-86. PubMed ID: 24747172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
    Heli U; Eeva J; Anne N; Tapani R; Liisa V
    Eur J Haematol; 2012 Jan; 88(1):87-8. PubMed ID: 22103782
    [No Abstract]   [Full Text] [Related]  

  • 8. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
    Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
    Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
    Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
    Takamatsu Y; Ogata K; Yamauchi K; Hara S; Kamimura T; Hayashi S; Suzumiya J; Tamura K
    Jpn J Clin Oncol; 2005 Jul; 35(7):400-3. PubMed ID: 15976066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
    Huttunen P; Taskinen M; Vettenranta K
    Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: intravenous versus oral busulfan--perhaps not as different as suggested.
    Slattery JT
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):282-4. PubMed ID: 12720221
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
    Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
    Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors.
    Hilger RA; Harstrick A; Eberhardt W; Oberhoff C; Skorzec M; Baumgart J; Seeber S; Scheulen ME
    Cancer Chemother Pharmacol; 1998; 42(2):99-104. PubMed ID: 9654108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Wachowiak J; Sykora KW; Cornish J; Chybicka A; Kowalczyk JR; Gorczyńska E; Choma M; Grund G; Peters C;
    Bone Marrow Transplant; 2011 Dec; 46(12):1510-8. PubMed ID: 21297673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
    Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.